No Data
No Data
BrightGene Gets Nod to Trial Salmeterol Fluticasone Inhalation Powder
Some Confidence Is Lacking In BrightGene Bio-Medical Technology Co., Ltd. (SHSE:688166) As Shares Slide 29%
Brightgene Bio-Medical Technology Co., Ltd. (688166.SH): The clinical trial approval notice for Salmeterol Fluticasone Propionate Inhalation Powder has been obtained.
On August 1st, Gelunhui reported that Brightgene Bio-Medical Technology Co., Ltd. (688166.SH) announced that its holding subsidiary, Aitai Mei (Suzhou) Pharmaceutical Technology Co., Ltd. (referred to as “Aitai Mei”), has recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, approving Aitai Mei to conduct clinical trials of Salmeterol Fluticasone Inhalation Powder for adults and children with asthma.
Retail Investors Invested in BrightGene Bio-Medical Technology Co., Ltd. (SHSE:688166) up 7.7% Last Week, Insiders Too Were Rewarded
Brightgene Bio-Medical Technology Co., Ltd. (688166.SH) plans to distribute RMB 0.96 per 10 shares in 2023. The ex-right and ex-dividend date is July 4th.
Brightgene Bio-medical Technology Co., Ltd. (688166.SH) announced that it plans to distribute cash to all shareholders in 2023 at a rate of 10 shares per share...
BrightGene Bio-Medical Technology Co., Ltd.'s (SHSE:688166) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
No Data